Successful Treatment of Histiocytic Sarcoma and Concurrent HIV Infection Using a Combination of CHOP and Antiretroviral Therapy

Kosuke Narita¹, Rintaro Noro¹, Masahiro Seike¹, Masaru Matsumoto¹, Kazue Fujita¹, Jiro Matsumura², Mikiko Takahashi³, Masashi Kawamoto⁴ and Akihiko Gemma¹

Abstract

Histiocytic sarcoma (HS) is a rare malignancy of soft tissues with an unknown etiology. The CHOP (cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride and prednisolone) regimen is often adopted as first-line chemotherapy; however, its therapeutic efficacy against HS is usually low. We herein first present the case of a patient with HS who was infected with human immunodeficiency virus-1 (HIV) in whom treatment with a combination of CHOP and antiretroviral therapy (ART) was successful. The patient has been in complete remission for 12 months following the discontinuation of chemotherapy under continuous ART. This case report may help to promote further investigation of both HS and HIV-related malignancy.

Key words: histiocytic sarcoma, CHOP, human immunodeficiency virus-1 (HIV), antiretroviral therapy (ART)


Introduction

Histiocytic sarcoma (HS) is a rare neoplasm of soft tissues (1). Generally, the disease involves the intestinal tract, skin and soft tissues. HS can occur in individuals of all ages, from infants to the elderly. The gender predominance is unclear. HS patients with solitary lesions usually have systemic symptoms, such as fever and weight loss. The diagnostic criteria for HS are based on immunohistochemistry (1) and are characterized by histiocytic markers, including CD68, CD163 and lysozyme. However, the pathogenesis of this disease remains unclear. It may arise from pluripotent germ cells and hematological malignancies, including malignant lymphoma, leukemia and myelodysplasia (2-4). Combination chemotherapy, such as CHOP (cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride and prednisolone), can be used as first-line chemotherapy in HS patients with advanced-stage disease (5, 6). However, the prognosis is unfavorable due to the poor response to chemotherapy.

Immunodeficiency is recognized to be a risk factor for various tumors in HIV-infected patients (7). For example, the frequency of Kaposi’s sarcoma, non-Hodgkin lymphoma and liver cancer is higher among HIV-positive patients than among HIV-negative patients. On the other hand, some malignancies are considered to be unrelated to HIV, including prostate, lung and colorectal cancers (8, 9). HS has not yet been reported in HIV-infected patients.

We herein present the first case of HS in an HIV-positive patient who was successfully treated with a combination of CHOP and antiretroviral therapy (ART).

Case Report

A 61-year-old man presented with a two-month history of a dry cough and generalized fatigue. The patient had a good performance status [Eastern Cooperative Oncology Group Performance Status Scale (ECOG PS) 0]. On a physical ex-
amination, a subcutaneous tumor was found in the lower left abdomen. Chest radiography revealed multiple tumor lesions in both lung fields (Fig. 1a). Computed tomography (CT) showed multiple tumors distributed throughout the body (i.e., in the lungs, heart, liver, kidneys, adrenal glands, bone and intra-abdominal space). Positron emission tomography and computed tomography (PET-CT) demonstrated intense accumulation of fluorine-18 fluorodeoxyglucose ($^{18}$F-FDG) in the tumors, and the highest maximum standardized uptake value (SUVmax) was 12.3 in the tumor located in the heart (Fig. 2). The intra-abdominal tumor was 53×31 mm in size and located adjacent to the left common iliac artery. A surgical biopsy of the intra-abdominal mass was performed. Hematoxylin and eosin staining revealed infiltration by atypical multinucleated cells with abundant cytoplasm and inflammatory cells (Fig. 3a, b). Immunohistochemistry showed strong CD68 (DakoCytomation, Glostrup, Denmark; Fig. 3c) and S-100 (DakoCytomation, Glostrup, Denmark; Fig. 3d) staining, weak marginal positivity for CD1a (Beckman Coulter, CA, USA; Fig. 3e) and a lack of CD3 and CD20 (DakoCytomation, Glostrup, Denmark). Although no immunohistochemical evaluations of CD163 were performed, the CD68 expression was confirmed in the tumor cells, and the pathological findings fulfilled the diagnostic criteria for histiocytic sarcoma (1). A diagnosis of Kaposi’s sarcoma was ruled out because immunohistochemistry using

Figure 1. Chest radiography before and after treatment with CHOP and ART. (a) Multiple tumors were confirmed in both lung fields before treatment. (b) The bilateral lung lesions were completely diminished after treatment with CHOP and ART.

Figure 2. PET-CT before treatment with CHOP and ART. (a) A whole-body scan revealed multiple tumors with accumulation of $^{18}$F-FDG. (b) The lesions in the heart and lungs exhibited high uptake. (c) $^{18}$F-FDG was also intensely accumulated in the intra-abdominal mass.
anti-human herpes virus-8 (HHV-8) antibodies was negative in tumor samples obtained via a CT-guided biopsy of the liver metastases. One of the major differential diagnoses in this case was Langerhans cell sarcoma (LCS). LCS consistently expresses CD1a and S-100 (10). S-100 proteins were detected in our case. However, the tumor cells did not exhibit an expression of CD1a. Therefore, a diagnosis of LCS was ruled out, and the final pathological diagnosis was HS according to the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues 4th edition 2008 (1, 10). On the other hand, laboratory tests confirmed the presence of both HIV-1 antigens and antibodies, and the plasma HIV-1 RNA level was 27,000 copies/mL (Fig. 4a). The CD4-positive lymphocyte count was only 83/μL (Fig. 4b). Moreover, neither HHV-8 DNA, cytomegalovirus antigens nor human T-cell leukemia virus-I (HTLV-I) antibodies were detected in the blood. There were also no abnormal findings in the blood chemistry or complete blood cell count, except for the decreased lymphocyte count. Therefore, the patient was diagnosed as having HS with HIV infection.

The patient was treated with ART (lamivudine 300 mg/day, abacavir sulfate 600 mg/day and raltegravir 800 mg/day) for HIV because this regimen has the advantage of a relatively low frequency of adverse effects, such as unfavor-
able interactions with antitumor drugs (11). Trimethoprim/ sulfamethoxazole and fluconazole were administered to prevent Pneumocystis jirovecii pneumonia and candidiasis. In addition, six cycles of CHOP (600 mg/m² of cyclophosphamide, 1.4 mg/m² of vincristine sulfate and 50 mg/m² of doxorubicin hydrochloride on day 1 with 100 mg/day of oral prednisolone on days 1-5) were administered at 3-week intervals. The patient tolerated the entire course of chemotherapy well. Following the initiation of ART, the HIV viral load decreased dramatically, with a corresponding increase in the CD4 count (Fig. 4). Follow-up chest radiography and PET-CT showed dramatic decreases in the size of the pulmonary tumors and intra-abdominal mass after the six courses of CHOP (Fig. 1b and Fig. 5). The patient was judged as having a complete response and has remained in remission for 12 months after the discontinuation of chemotherapy under continuous ART.

**Discussion**

To the best of our knowledge, there are no reports of HS occurring in patients with HIV infection. The etiology of HS remains unknown, and no relationships between HS and viral infections, including HIV, have been established (1). HIV infection is characterized by the progressive suppression of acquired immunity (i.e., acquired immunity deficiency syndrome, AIDS). HIV/AIDS patients are immunocompromised enough to suffer from opportunistic infectious diseases. In addition, HIV-infected patients are at greater risk of developing certain malignancies, such as Kaposi’s sarcoma and non-Hodgkin lymphoma, that are known to be HIV-associated malignancies (9). Immunodeficiency caused by HIV infection is thought to increase the incidence of HIV-associated malignancy (7). However, the role of HIV infection in the pathogenesis of malignant tumors is not fully understood.

In general, the prognosis of HS patients is poor. The median survival is reported to be <12 months (5, 12-17). Combination treatments, such as CHOP, can be used as first-line chemotherapy in advanced-stage HS patients (5, 6). However, HS patients often relapse after CHOP and may require additional therapies, such as second-line chemotherapy and autologous hematopoietic stem-cell transplantation (6, 18). The patient presented here was successfully treated with a combination of CHOP and ART. ART effectively decreased the level of HIV-1 RNA and increased the level of CD4 cells in the patient. The reduction in the HIV-1 viral load and the improvement in the CD4 count accomplished by ART are expected to result in better tolerance of chemotherapy and prolonged overall survival (19). ART may improve the immune response against HS and enhance the antitumor effects of CHOP.

In conclusion, to the best of our knowledge, this is the first report of the successful treatment of an HIV-infected HS patient using CHOP and ART. The pathogenesis of HS remains unknown; however, this case may help to further the investigation of both HS and HIV-related malignancies.

The authors state that they have no Conflict of Interest (COI).

**Acknowledgement**

The authors thank Dr. Tsunekazu Hishima (Department of Pa-

---

**Figure 5.** PET-CT after treatment with CHOP and ART. (a) A whole-body scan confirmed that there were no lesions with 18F-FDG uptake. (b) The tumors in the heart and lungs disappeared completely. (c) PET-CT also showed no recurrence of the intra-abdominal tumor.
thology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan) for performing the immunohistochemical analysis of HHV-8.

References